Evidence map›Paper›PMID 33767380›Full record

ArticleActa pharmacologica Sinica2022

Mitochondrial aldehyde dehydrogenase (ALDH2) rescues cardiac contractile dysfunction in an APP/PS1 murine model of Alzheimer's disease via inhibition of ACSL4-dependent ferroptosis.

Zhi-Yun Zhu, Yan-Dong Liu, Yan Gong, Wei Jin, Elena Topchiy, Subat Turdi, Yue-Feng Gao, Bruce Culver, Shu-Yi Wang, Wei Ge and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 1 pooled it
13.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 1 synthesis or guideline pooled it, 133 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. ALDH2 Mediated Ferroptosis Regulation in Ischemia-Reperfusion Injury.Journal of cellular and molecular medicine · 2026
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 2 countries.

Zhi-Yun Zhu *Jiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang, 330006, China.
Yan-Dong Liu *The Second Department of Cardiology, The Third Hospital of Nanchang, Nanchang, 330009, China.
Yan Gong *The Second Department of Cardiology, The Third Hospital of Nanchang, Nanchang, 330009, China.
Wei Jin *The Second Department of Cardiology, The Third Hospital of Nanchang, Nanchang, 330009, China.
Elena TopchiyUniversity of Wyoming College of Health Sciences, Laramie, WY, USA.
Subat TurdiUniversity of Wyoming College of Health Sciences, Laramie, WY, USA.
Yue-Feng GaoUniversity of Wyoming College of Health Sciences, Laramie, WY, USA.
Bruce CulverUniversity of Wyoming College of Health Sciences, Laramie, WY, USA.
Shu-Yi WangUniversity of Wyoming College of Health Sciences, Laramie, WY, USA.
Wei GeDepartment of General Practice, Xijing Hospital, the Air Force Military Medical University, Xi'an, 710032, China.
Wen-Liang ZhaDepartment of Surgery, Clinic Medical College, Hubei University of Science and Technology, Xianning, 437100, China.
Jun RenUniversity of Wyoming College of Health Sciences, Laramie, WY, USA. jren_aldh2@outlook.com.
Zhao-Hui PeiThe Second Department of Cardiology, The Third Hospital of Nanchang, Nanchang, 330009, China. peizhaohui@email.ncu.edu.cn.
Xing QinUniversity of Wyoming College of Health Sciences, Laramie, WY, USA. bravoqx@126.com.
University of Wyoming · USThird Hospital of Nanchang · CNXijing Hospital · CNHubei University of Science and Technology · CNJiangxi Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alzheimer's disease (AD) is associated with high incidence of cardiovascular events but the mechanism remains elusive. Our previous study reveals a tight correlation between cardiac dysfunction and low mitochondrial aldehyde dehydrogenase (ALDH2) activity in elderly AD patients. In the present study we investigated the effect of ALDH2 overexpression on cardiac function in APP/PS1 mouse model of AD. Global ALDH2 transgenic mice were crossed with APP/PS1 mutant mice to generate the ALDH2-APP/PS1 mutant mice. Cognitive function, cardiac contractile, and morphological properties were assessed. We showed that APP/PS1 mice displayed significant cognitive deficit in Morris water maze test, myocardial ultrastructural, geometric (cardiac atrophy, interstitial fibrosis) and functional (reduced fractional shortening and cardiomyocyte contraction) anomalies along with oxidative stress, apoptosis, and inflammation in myocardium. ALDH2 transgene significantly attenuated or mitigated these anomalies. We also noted the markedly elevated levels of lipid peroxidation, the essential lipid peroxidation enzyme acyl-CoA synthetase long-chain family member 4 (ACSL4), the transcriptional regulator for ACLS4 special protein 1 (SP1) and ferroptosis, evidenced by elevated NCOA4, decreased GPx4, and SLC7A11 in myocardium of APP/PS1 mutant mice; these effects were nullified by ALDH2 transgene. In cardiomyocytes isolated from WT mice and in H9C2 myoblasts in vitro, application of Aβ (20 μM) decreased cell survival, compromised cardiomyocyte contractile function, and induced lipid peroxidation; ALDH2 transgene or activator Alda-1 rescued Aβ-induced deteriorating effects. ALDH2-induced protection against Aβ-induced lipid peroxidation was mimicked by the SP1 inhibitor tolfenamic acid (TA) or the ACSL4 inhibitor triacsin C (TC), and mitigated by the lipid peroxidation inducer 5-hydroxyeicosatetraenoic acid (5-HETE) or the ferroptosis inducer erastin. These results demonstrate an essential role for ALDH2 in AD-induced cardiac anomalies through regulation of lipid peroxidation and ferroptosis.

Indexed as

Disease Models, AnimalAldehyde Dehydrogenase, MitochondrialAlzheimer DiseaseAmyloid beta-Protein PrecursorAnimalsCoenzyme A LigasesDose-Response Relationship, DrugFerroptosisMiceMice, TransgenicMolecular StructureMyocardial ContractionPresenilin-1Structure-Activity RelationshipAcsl4 protein, mouseAldehyde Dehydrogenase, MitochondrialALDH2 protein, mouseAmyloid beta-Protein PrecursorAPP protein, mouseCoenzyme A LigasesPresenilin-1presenilin 1, mouseAlda-1ALDH2Alzheimer’s diseasecardiac functionferroptosislandscape perceptionslipid peroxidationtolfenamic acid; triacsin C; 5-HETE; erastin

Identifiers

PMID33767380
PMCPMC8724276
OpenAlexW3136232395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.